A drenocorticotropic hormone (ACTH) is a 39-amino acid peptide and is the primary regulator of adrenal glucocorticoid (GC) synthesis and secretion (1) (2) (3) . The regulation of ACTH and cortisol production involves distinct and complex pathways, including classic circadian rhythm (4, 5) and both psychological and physical stress (6) . Excess ACTH secretion is associated with 2 rare disease indications, congenital adrenal hyperplasia (CAH) and Cushing disease. CAH results from a variety of genetic defects in the adrenal steroidal biosynthesis pathway with the most common mutation in 21-hydroxylase (7, 8) . Patients are characterized by a reduction or loss of cortisol synthesis and excessive corticotropin-releasing hormone and ACTH secretion due to the removal of negative regulation by cortisol (9) . The elevated ACTH levels stimulate the adrenal cortex to synthesize excess cortisol precursors and androgens (10) , resulting in significant physiological changes, including virilization, short stature, infertility, and psychological effects (11) . Standard therapy for CAH patients consists of GC and if necessary mineralocorticoid supplementation. However, treatment with physiological levels of GC frequently does not adequately reduce ACTH and androgen levels (12) . GC replacement therapy is a delicate balance between preventing ACTH-induced androgen excess and avoiding supraphysiological levels of GC that can lead to severe Cushingoid-like side effects (13) .
Cushing disease is characterized by an ACTH-secreting pituitary adenoma that stimulates excess cortisol production (14) . Chronic exposure to high levels of cortisol results in a wide variety of clinical features, including purple striae, hypertension, insulin resistance, and depression (15, 16) . Surgery is the first-line treatment, with medical therapy used for patients who are not candidates for surgery or when surgery fails to restore normal cortisol levels. Current medical therapy approaches suffer from low efficacy rates and significant adverse effects (17) (18) (19) (20) .
In this study, we report on a potent neutralizing monoclonal antibody targeting ACTH. The antibody, ALD1613, blocks ACTH-induced MC2R signaling and results in a reduction of circulating GC levels in rats and cynomolgus monkeys. ALD1613 represents a proof of principle for controlling ACTH-driven pathophysiology with a monoclonal antibody.
Materials and Methods

Cells
Chinese hamster ovary (CHO)-K1 cells stably transfected with MC1R, MC2R, MC3R, MC4R, or MC5R were from Thermo Fisher (Carlsbad, CA). Y1 cells were obtained from American Type Culture Collection (Manassas, VA).
Identification of anti-ACTH antibodies
Keyhole limpet hemocyanin-conjugated ACTH (1-39) (Bachem, Torrance, CA) was mixed with unconjugated peptide equal to the calculated mass of keyhole limpet hemocyanin for a final peptide concentration of 3.75 mg/mL. New Zealand White rabbits were immunized with 200 mg in 0.5 mL of Dulbecco's phosphate-buffered saline mixed with 0.5 mL of complete Freund's adjuvant. Three boost injections of 100 mg were performed on days 21, 42, and 60. Antibodies against ACTH were identified by antigen recognition [enzyme-linked immunosorbent assay (ELISA)] of conditioned B cell culture supernatants as previously described (21) . ALD1613 was humanized by grafting the complementary determining regions into the closest human V region light and heavy chain framework sequences (V1-5 and V3-66, respectively) as previously described (22) . To retain affinity, 5 positions in the heavy chain human framework sequence were reverted to the rabbit sequence.
ALD1613 binding kinetics
ALD1613 binding affinity for ACTH was estimated using surface plasmon resonance on a ProteOn™ XPR36 (Bio-Rad Laboratories, Hercules, CA) as previously described (23) . A dilution series of human (American Peptide, Sunnyvale, CA) or rat (Bachem) ACTH (454 ng/mL to 5.6 ng/mL) was used to query ALD1613 with association times of 200 seconds and dissociation times of 30 to 200 minutes. ALD1613 binding affinities for human a-melanocyte-stimulating hormone (a-MSH) and corticotropin-like intermediate peptide (CLIP; American Peptide) were estimated using peptide concentrations ranging from 1.66 mg/mL to 0.02 mg/mL and 2.46 mg/mL to 0.03 mg/mL, respectively, with dissociation times of 1 to 10 minutes.
ACTH-induced cyclic adenosine monophosphate production in MC2R-expressing CHO cells and Y1 cells 
Rat pharmacodynamic studies
Studies were conducted at Bolder BioPATH (Boulder, CO) according to protocols approved by their Institutional Animal Care and Use Committee. Antibodies were administered by intravenous (IV) bolus (tail vein). Blood draws were collected between 2:00 and 3:00 PM (to minimize the variation due to diurnal regulation) via the tail vein into K 3 -EDTA tubes and processed into plasma. Male Lewis rats (N = 8) were injected with 0.1, 1, or 10 mg/kg ALD1613 or 10 mg/kg control isotype antibody (CA) on day 0. To limit stress during blood collections, rats were placed in heated anesthesia chambers (heat pads) for 10 minutes, isoflurane was introduced into the chamber for 7 to 10 minutes, and blood was collected. Plasma corticosterone levels were assessed using a corticosterone enzyme immunoassay kit (Enzo Life Sciences, Famingdale, NY) according to the manufacturer's protocol. The lower limit of quantification (LLOQ) was 16 ng/mL. Intra-assay coefficient of variation (CV) was 6.6% to 8.4% and the interassay CV was 7.8% to 13.1%. The manufacturer's reported testing of 10 compounds for crossreactivity and deoxycorticosterone was 28.6%, whereas the other 9 compounds were ,1.8%.
Male Lewis rats (N = 5) were implanted on day 0 with an Alzet pump (Durect, Cupertino, CA, model 2ML1; 5 mL/h) delivering vehicle or rat ACTH (Bachem) at a rate of 15, 50, or 150 mg/kg/d. Forty-eight hours later rats were injected with 10 mg/kg ALD1613 or a CA. Body weights were recorded daily. Blood draws were collected between 2:00 and 3:00 PM on days 0, 2, 3, 5, and 8.
Male Lewis rats (N = 8) were injected with 10 mg/kg ALD1613 or a CA on day 0. Blood was collected between 2: 00 and 3:00 PM on days 25, 22, 2, and 6 as described previously. On days 3 and 5, rats were placed in a heated Plexiglas cylinder restraint tube for 10 minutes and subsequently bled (tail vein) using the rat restrainer without anesthesia.
Cynomolgus monkey pharmacodynamic study
Cynomolgus monkey studies were conducted at Charles River Laboratories (Wilmington, MA) according to protocols approved by their Institutional Animal Care and Use Committee. Naive male animals (N = 3) were injected IV with 10 mg/kg ALD1613 or a CA on days 1 and 7. Blood samples were collected between 2:00 and 3:00 PM by venipuncture, and analyses included serum clinical chemistries, complete blood counts (CBCs), plasma cortisol, and total ALD1613 levels. Cortisol levels determined with a Cortisol parameter assay kit (R&D Systems, Minneapolis, MN) per manufacturer's instructions.
The LLOQ was 3.2 ng/mL. Intraassay CV was 5.4% to 9.2%, and the interassay CV was 9.3% to 21.2%. The manufacturer reported testing of 9 compounds similar to cortisol that showed minimal cross-reactivity in the assay (,4.5%). Plasma aldosterone levels were assessed using an aldosterone enzyme immunoassay kit (Enzo Life Sciences) according to the manufacturer's protocol. The LLOQ was 39 pg/mL. Intraassay CV was 4.4% to 6.6% and the interassay CV was 10.8% to 18%. The manufacturer reported testing of 7 compounds similar to aldosterone that showed minimal crossreactivity in the assay (,0.4%). Total ALD1613 levels were determined by ELISA. Samples in 10% plasma matrix were incubated with goat anti-human immunoglobulin G (SouthernBiotech, Birmingham, AL) immobilized on MSD high bind microtiter plates (Meso Scale Discovery, Rockville, MD). ALD1613 was detected with biotinylated goat anti-human immunoglobulin G (H+L) (Bethyl Laboratories, Montgomery, TX) and SULFO-TAG-labeled streptavidin. Electrochemiluminescence signals were measured on an MSD Sector Imager 2400 (Meso Scale Discovery).
Statistical methods
Graphed data were expressed as the mean 6 standard deviation. All statistical tests were nonparametric, 2-tailed MannWhitney tests with a significance level of P # 0.05 (GraphPad Software, La Jolla, CA, Prism 6). ALD1613 pharmacokinetic parameters were calculated using WinNonLin (Pharsight, Mountain View, CA).
Results
ALD1613 identification and binding kinetics
A large collection of ACTH-reactive antibodies was identified from splenic B cell cultures of ACTH-immunized rabbits. A subset of this collection was demonstrated to inhibit ACTH-induced MC2R signaling and 1 of these antibodies, ALD1613, was humanized and further characterized. ALD1613 bound with high affinity to human and rat ACTH with similar kinetic parameters ( Table 1) .
Tissue-specific processing of ACTH to a-MSH and CLIP occurs in several cell types, and therefore the specificity of ALD1613 to ACTH was verified by determining the equilibrium dissociation constants for these peptides. ALD1613 had no detectable binding to a-MSH and significantly lower affinity for CLIP (Table 1) than for ACTH.
ALD1613 inhibits ACTH in vitro activity
ALD1613 inhibited ACTH-induced cAMP accumulation in CHO cells transfected with the ACTH receptor (MCR2) and MRAP with a 50% inhibitory concentration (IC 50 ) of 102 pM [ Fig. 1(A) ]. ACTH interacts with other melanocortin receptors (MC1R, MC3R, MC4R, and MC5R) with varying affinities (24) , and ALD1613 was demonstrated to inhibit, in a dose-dependent manner, ACTH-induced signaling via these 4 melanocortin receptors (Supplemental Materials and Methods; Supplemental Fig. 1 ). Additionally, ALD1613 inhibited ACTH-induced cAMP production in Y1 cells, a mouse adrenal cell line expressing endogenous MC2R and MRAP (25) . ACTH (2.4 nM) induced cAMP levels in Y1 cells whereas preincubation of ACTH (2.4 nM) with increasing concentrations of ALD1613 inhibited ACTH-induced cAMP production with an IC 50 of 0.82 nM [ Fig. 1(B) ].
ALD1613 reduced corticosterone levels in rats
Male Lewis rats were dosed IV with 0.1, 1, or 10 mg/kg ALD1613 or 10 mg/kg CA on day 0. A single dose of ALD1613 at either 1 or 10 mg/kg significantly reduced corticosterone levels (P , 0.01) to below the LLOQ of the assay (16 ng/mL) at all time points after antibody administration (Fig. 2) . Administration of ALD1613 at 0.1 mg/kg significantly reduced corticosterone levels (P , 0.01) on days 1 and 3, after which corticosterone levels were similar to the CA-treated group (Fig. 2) .
ALD1613 inhibited an ACTH-induced phenotype in rats
Corticosterone levels in the previous experiment were measured during the expected nadir of secretion. To evaluate the efficacy of ALD1613 under conditions with higher ACTH levels, Alzet pumps were implanted to continuously deliver 15, 50, or 150 mg/kg/d rat ACTH or vehicle (phosphate-buffered saline). Forty-eight hours after pump implantation, 10 mg/kg ALD1613 or a CA was administered IV. Rats dosed with ACTH and a CA displayed a dose-dependent increase in plasma corticosterone levels [ Fig. 3(A) ] and a decrease in body weight [ Fig. 3(B) ] consistent with previous reports (26, 27) . A single dose of ALD1613 (10 mg/kg) reduced corticosterone levels proportional to the ACTH dose. Treatment with 15 mg/kg/d ACTH and ALD1613 resulted in significantly lower corticosterone levels (P , 0.01) than for rats administered the same dose of ACTH and a CA on all days after antibody administration [ Fig. 3(C) ]. Rats dosed 
Modulation of restraint stress response in rats
Restraint stress results in transient ACTH-dependent increases in plasma corticosterone levels (28) . Rats were dosed with 10 mg/kg ALD1613 or a CA on day 0. Blood draws without restraint stress were taken on days 25, 22, 2, and 6 and following restraint stress on days 3 and 5. Administration of a CA did not alter corticosterone levels compared with predose but were significantly elevated (P , 0.05) by restraint stress [ Fig. 2(I) ]. Administration of ALD1613 significantly reduced corticosterone levels on days 2 and 6 (P , 0.001 and P , 0.01, respectively) in the absence of restraint stress. Following restraint stress (days 3 and 5), corticosterone levels were induced in animals dosed with ALD1613 but significantly blunted (P , 0.001) compared with CA-treated animals [ Fig. 3(I) ].
ALD1613 reduced cortisol levels in cynomolgus monkeys
Naive male cynomolgus monkeys (N = 3) were dosed IV with 10 mg/kg ALD1613 or CA on days 1 and 7. Plasma cortisol levels, clinical chemistries, CBCs, and body weights were monitored up to day 57. The group mean cortisol levels in the CA-treated animals varied between 161 and 266 ng/mL during the duration of the study [ Fig. 3(A) ]. Following administration of ALD1613, group mean cortisol levels were reduced from predose levels of 350 ng/mL to between 63 and 146 ng/mL during the 57-day study period [Fig. 3(A) ], with reductions in press.endocrine.org/journal/endoindividual animals of 50% to 90% within 2 days of antibody administration. Plasma aldosterone levels were determined and no significant differences between the groups were observed [ Fig. 4(B) ]. Additionally, no significant changes in clinical chemistries, CBCs, or body weights were observed (data not shown). Determination of the total ALD1613 levels in plasma [ Fig. 3(C) ] resulted in an estimated half-life of 11.5 days (276.6 hours), and using simple allometric species scaling (29), the human half-life is estimated to be ;30 days.
Discussion
We describe a novel approach to target ACTH-related pathologies using a potent monoclonal antibody, ALD1613, that displays high specificity and affinity against ACTH and neutralized ACTH-induced signaling in vitro. The specificity, high affinity, and neutralizing activity displayed enabled the in vivo evaluation of the consequences of selective and durable inhibition of ACTH pharmacology. A single administration of ALD1613 to rats resulted in a rapid and substantial reduction of corticosterone levels that was durable throughout the 2-week study period. Plasma samples were collected at the time of the expected nadir of corticosterone levels, and therefore it is possible that during the diurnal spike increased corticosterone levels were present similar to the observed induction of corticosterone seen with restraint stress in the presence of ALD1613. The data are proof of concept for the use of a monoclonal antibody to modulate the activity of pituitary-derived ACTH to stimulate GC secretion from the adrenal glands.
Two approaches were taken to elevated ACTH levels in rats. First, ACTH and corticosterone were chronically elevated through implanted infusion pumps delivering various levels of rat ACTH. A single administration of ALD1613 (10 mg/kg) protected against the ACTH-induced phenotypic changes proportional to the ACTH dose. The results demonstrated that a single dose of ALD1613 in the context of variable levels of ACTH resulted in different steady-state levels of plasma corticosterone that were reflected in the degree of protection against loss of body weight. These data established that ALD1613 can modify the ACTH-driven GC levels in the context of significant levels of target antigen and provided insight on the dosing strategy that would be needed to manage chronically elevated ACTH levels encountered in CAH or Cushing disease patients. Second, ACTH levels were transiently elevated by subjecting rats to restraint stress. In the presence of ALD1613, rats responded to restraint stress by inducing corticosterone, but to levels significantly lower than those in control animals. The induction of corticosterone under restraint stress in the presence of ALD1613 was not due to antigen saturation of the antibody binding sites because ALD1613 effectively inhibited ACTH activity under subsequent nonrestraint stress conditions. The incomplete suppression of plasma corticosterone following restraint stress by ALD1613 may be due to transiently elevated ACTH levels and increased adrenal sensitivity to ACTH via direct innervation of the adrenal cortex (30) enabling modest MC2R signaling.
Administration of ALD1613 on days 1 and 7 to cynomolgus monkeys demonstrated a reduction in plasma cortisol levels that persisted for ;2 months. In contrast to the results seen with wild-type rats, cortisol levels in the cynomolgus monkeys administered ALD1613 were well above the assay LLOQ (3.2 ng/mL), including following the second dose of ALD1613, when high levels of free antibody would be expected in circulation. The reduced and stable cortisol levels suggest that there was consistently sufficient free ALD1613 to reduce but not abolish ACTH-induced cortisol levels. It is possible that the observed cortisol levels represent transient spikes due to the stress of the blood collection procedures, as the animals were restrained within the housing unit and blood was collected without the use of anesthesia and that steady-state 22) and following administration of 10 mg/kg CA or ALD1613. Blood draws were performed in the absence of restraint stress (days 25, 22, 2 and 6) or following restraint stress (days 3 and 5). *P , 0.05, values that significantly differ from same group not subjected to restraint stress. **P , 0.01, values of group treated with ALD1613 that significantly differ from the group treated with CA. ***P , 0.001, values of group treated with ALD1613 that significantly differ from the group treated with CA. levels of cortisol were lower. The collective data demonstrated that ALD1613 can significantly and durably modulate GC production in both rats and cynomolgus monkeys.
Two clinical indications characterized by high ACTH levels that could potentially benefit from the therapeutic strategy described in this study are CAH and Cushing disease. CAH is characterized by a substantial decrease or loss of cortisol production and elevated levels of ACTH that stimulate the production of cortisol intermediates and excess androgens. The current treatment paradigm for CAH is a delicate balance of GC replacement to inhibit excess ACTH and androgen production while limiting the severe side effects associated with the use of supraphysiological levels of GCs (13) . ALD1613 demonstrates that an anti-ACTH antibody can limit bioactive ACTH levels and has the potential to not only reduce androgen excess but also allow for a reduction in the supraphysiological levels of GCs often administered to patients. Adult CAH patients require increased GC supplementation under stressful conditions (such as infection, surgery, or psychological stress) to avoid adrenal crises. We demonstrated that rats have a blunted GC response to stress, and therefore it is possible that exposure to a potent neutralizing ACTH antibody such as ALD1613 would require GC supplementation in times ofsubstantial physical or psychological stress. Cushing disease is caused by a pituitary adenoma secreting excess ACTH, resulting in increased adrenal cortisol production. The collective in vivo data presented in the present study demonstrate the ability of ALD1613 to modulate ACTH activity and reduce plasma GC levels. The rapid, substantial, and durable decrease in ACTH-induced GC secretion observed in the rats and cynomolgus monkeys suggests that a monoclonal antibody such as ALD1613 has the potential to control excess cortisol levels in patients with Cushing disease.
